JNJ-2113
- Generic Name
- JNJ-2113
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
- Conditions
- Plaque Psoriasis
- Interventions
- Drug: Matching Placebo to UstekinumabDrug: Matching Placebo to JNJ-77242113
- First Posted Date
- 2025-04-18
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 675
- Registration Number
- NCT06934226
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
- Conditions
- Arthritis, Psoriatic
- Interventions
- First Posted Date
- 2025-03-17
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 540
- Registration Number
- NCT06878404
- Locations
- 🇯🇵
Sasebo Chuo Hospital, Sasebo, Japan
🇪🇸Corporacio Sanitari Parc Tauli, Sabadell, Spain
🇪🇸Hosp. Univ. Marques de Valdecilla, Santander, Spain
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced Participants With Active Psoriatic Arthritis
- First Posted Date
- 2025-02-04
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 750
- Registration Number
- NCT06807424
- Locations
- 🇭🇺
Betegapolo Irgalmas Rend Budai Irgalmasrendi Korhaz, Budapest, Hungary
🇭🇺Qualiclinic Kft, Budapest, Hungary
🇭🇺MAV Korhaz es Rendelointezet, Szolnok, Hungary
A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
- Conditions
- Erythrodermic PsoriasisGeneralized Pustular Psoriasis
- Interventions
- First Posted Date
- 2024-03-06
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 19
- Registration Number
- NCT06295692
- Locations
- 🇯🇵
JR Sapporo Hospital, Hokkaido, Japan
🇯🇵Ichinomiya Municipal Hospital, Ichinomiya, Japan
🇯🇵Teikyo University Hospital, Itabashi Ku, Japan
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
- Conditions
- Plaque Psoriasis
- Interventions
- Drug: JNJ-77242113 Matching Placebo
- First Posted Date
- 2024-01-24
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 731
- Registration Number
- NCT06220604
- Locations
- 🇩🇪
Universitatsmedizin der Johannes Gutenberg Universitat Mainz, Mainz, Germany
🇵🇱WroMedica I Bielicka A Strzalkowska s c, Wroclaw, Poland
🇺🇸Essential Medical Research, Tulsa, Oklahoma, United States
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
- Conditions
- Plaque Psoriasis
- Interventions
- Drug: JNJ-77242113 Matching Placebo
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 774
- Registration Number
- NCT06143878
- Locations
- 🇭🇺
SZTE AOK Szent-Gyorgyi Albert Klinikai Kozpont, Borgyogyaszati és Allergologiai Klinika, Szeged, Hungary
🇭🇺Allergo-Derm Bakos Kft., Szolnok, Hungary
🇭🇺Medmare Egeszsegugyi Es Szolgaltato Bt., Veszprem, Hungary
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 311
- Registration Number
- NCT06095102
- Locations
- 🇺🇸
California Dermatology & Clinical Research Institute, Encinitas, California, United States
🇺🇸Forcare Clinical Research Inc, Tampa, Florida, United States
🇺🇸Hamilton Research LLC, Alpharetta, Georgia, United States
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 684
- Registration Number
- NCT06095115
- Locations
- 🇺🇸
Medical Dermatology Specialists, Phoenix, Arizona, United States
🇺🇸Johnson Dermatology, Fort Smith, Arkansas, United States
🇺🇸First OC Dermatology, Fountain Valley, California, United States
A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis
- Conditions
- Colitis, Ulcerative
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 252
- Registration Number
- NCT06049017
- Locations
- 🇺🇸
Clinnova Research, Anaheim, California, United States
🇺🇸Peak Gastroenterology Associates, Colorado Springs, Colorado, United States
🇺🇸I.H.S. Health. LLC, Kissimmee, Florida, United States
A Study of JNJ-77242113 Following Oral Administration in Healthy Chinese Adult Participants
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 30
- Registration Number
- NCT05703841
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.